Tags

Type your tag names separated by a space and hit enter

Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Biol Blood Marrow Transplant. 2009 Jun; 15(6):686-93.BB

Abstract

Multiple myeloma (MM) rarely occurs in patients 40 years of age and younger. This young age has been reported to correlate with improved survival in patients with MM. The objective of this study is to describe presenting features and outcomes of patients < or =40 years of age with MM who undergo autologous stem cell transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free survival (PFS) to patients aged 41-65 years. We performed a retrospective institutional review of all patients < or =40 years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from January 1, 1990, to July 31, 2007. Thirty-eight patients < or =40 years of age and 608 patients aged 41-65 were identified. There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the reported rate of 2%-4%. At diagnosis, there was an increased rate of renal failure in the young cohort compared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%. The rate of complete or partial response was similar between the groups at 79% and 83% in the young and older cohorts, respectively. Median PFS post-ASCT was 22.0 months (95% confidence interval [CI]: 16.1, 28.0), versus 26.9 months (95% CI: 24.0, 29.8) for patients aged 41-65 years (P = .66). Median OS from date of ASCT was also similar to those over 40 years: 68.1 months (95% CI: 39.0, 97.2) versus 80.7 months (95% CI: 68.1, 93.4); P = .90. Treatment-related mortality (TRM) was low at 2.6% and 2.3% in the young and older cohorts, respectively. Despite previous reports that young age is a positive prognostic marker, our study found OS post-ASCT is equivalent to those aged 41-65 years. This study emphasizes the importance of developing strategies to better the outcomes of young patients with MM.

Authors+Show Affiliations

Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale,AZ 85259, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19450753

Citation

Cheema, Parneet K., et al. "Age 40 Years and Under Does Not Confer Superior Prognosis in Patients With Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 15, no. 6, 2009, pp. 686-93.
Cheema PK, Zadeh S, Kukreti V, et al. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biol Blood Marrow Transplant. 2009;15(6):686-93.
Cheema, P. K., Zadeh, S., Kukreti, V., Reece, D., Chen, C., Trudel, S., & Mikhael, J. (2009). Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 15(6), 686-93. https://doi.org/10.1016/j.bbmt.2009.02.013
Cheema PK, et al. Age 40 Years and Under Does Not Confer Superior Prognosis in Patients With Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant. Biol Blood Marrow Transplant. 2009;15(6):686-93. PubMed PMID: 19450753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. AU - Cheema,Parneet K, AU - Zadeh,Sahar, AU - Kukreti,Vishal, AU - Reece,Donna, AU - Chen,Christine, AU - Trudel,Suzanne, AU - Mikhael,Joseph, Y1 - 2009/04/09/ PY - 2008/08/13/received PY - 2009/02/21/accepted PY - 2009/5/20/entrez PY - 2009/5/20/pubmed PY - 2009/9/29/medline SP - 686 EP - 93 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 15 IS - 6 N2 - Multiple myeloma (MM) rarely occurs in patients 40 years of age and younger. This young age has been reported to correlate with improved survival in patients with MM. The objective of this study is to describe presenting features and outcomes of patients < or =40 years of age with MM who undergo autologous stem cell transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free survival (PFS) to patients aged 41-65 years. We performed a retrospective institutional review of all patients < or =40 years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from January 1, 1990, to July 31, 2007. Thirty-eight patients < or =40 years of age and 608 patients aged 41-65 were identified. There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the reported rate of 2%-4%. At diagnosis, there was an increased rate of renal failure in the young cohort compared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%. The rate of complete or partial response was similar between the groups at 79% and 83% in the young and older cohorts, respectively. Median PFS post-ASCT was 22.0 months (95% confidence interval [CI]: 16.1, 28.0), versus 26.9 months (95% CI: 24.0, 29.8) for patients aged 41-65 years (P = .66). Median OS from date of ASCT was also similar to those over 40 years: 68.1 months (95% CI: 39.0, 97.2) versus 80.7 months (95% CI: 68.1, 93.4); P = .90. Treatment-related mortality (TRM) was low at 2.6% and 2.3% in the young and older cohorts, respectively. Despite previous reports that young age is a positive prognostic marker, our study found OS post-ASCT is equivalent to those aged 41-65 years. This study emphasizes the importance of developing strategies to better the outcomes of young patients with MM. SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/19450753/Age_40_years_and_under_does_not_confer_superior_prognosis_in_patients_with_multiple_myeloma_undergoing_upfront_autologous_stem_cell_transmplant_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083-8791(09)00112-8 DB - PRIME DP - Unbound Medicine ER -